• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CareDx to Report Second Quarter 2024 Financial Results

    7/16/24 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

    Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx's website at: investors.caredxinc.com.

    About CareDx – The Transplant Company

    CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240716115420/en/

    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Valantine Hannah sold $202,566 worth of shares (10,570 units at $19.16), decreasing direct ownership by 21% to 38,994 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/23/25 4:30:05 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Maag Peter sold $192,420 worth of shares (10,000 units at $19.24), decreasing direct ownership by 3% to 318,846 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/20/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Goldberg Michael was granted 12,103 shares, increasing direct ownership by 9% to 152,998 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:56:07 PM ET
      $CDNA
      Medical Specialities
      Health Care